Pcsk9 Inhibitors have transformed the management of dyslipidemia by providing powerful LDL cholesterol reduction for patients who do not reach target levels with statins alone or who are unable to tolerate conventional therapy. These monoclonal antibodies and emerging small-interfering RNA agents act on the PCSK9 pathway to increase hepatic LDL receptor recycling, resulting in sustained lowering of circulating LDL and, consequently, reduced cardiovascular risk. As guideline recommendations increasingly highlight these agents for secondary prevention and high-risk primary prevention, clinicians look to expert-led education and focused cardiology conference sessions to understand optimal patient selection, practical prescribing and long-term safety data. Positioned at the crossroads of lipidology and cardiovascular prevention, this topic is fundamental to contemporary cardiovascular risk management strategies.

The session begins by reviewing the biology of PCSK9, its role in LDL receptor degradation and the mechanistic rationale for inhibition. Attendees will examine clinical trial data demonstrating event reduction across diverse high-risk groups, including patients with established atherosclerotic cardiovascular disease, familial hypercholesterolemia and diabetes. The evidence for combining PCSK9 inhibitors with high-intensity statins and ezetimibe, as well as their impact on lipoprotein(a) and other lipid fractions, is presented in a clinically relevant way.

Practical aspects of initiating therapy are explored in depth. Participants learn how to identify appropriate candidates based on LDL thresholds, risk scores, prior events, statin intolerance and adherence issues. Dosing schedules, injection techniques, storage requirements and strategies to support long-term adherence are reviewed, with emphasis on patient education and shared decision-making. Case examples illustrate how to individualise therapy for elderly patients, those with polypharmacy and individuals concerned about injectable treatments.

Safety and tolerability profiles are discussed, including common side effects, injection-site reactions and long-term safety monitoring. The session also addresses health-system considerations such as cost-effectiveness, formulary pathways, reimbursement criteria and the role of lipid clinics in coordinating care.

Looking ahead, participants will explore emerging PCSK9-targeting technologies such as in-clinic and self-administered long-acting agents, gene-silencing approaches and combination therapies that aim to simplify dosing and enhance accessibility. Novel biomarkers, imaging tools and genetic insights that refine risk prediction and treatment thresholds are also considered. By the end of the session, clinicians will have a clear framework for integrating PCSK9 inhibitors into daily practice, ensuring that high-risk patients receive intensive, evidence-based lipid lowering to prevent future cardiovascular events. The session further highlights how multidisciplinary collaboration between cardiologists, endocrinologists, primary-care physicians and pharmacists can streamline identification of eligible patients and support continuity of care over many years. Practical communication tips are shared to help clinicians explain absolute risk reduction, expected LDL changes and timelines for benefit in a way that is meaningful and motivating for patients and families. This holistic perspective ensures that powerful lipid-lowering therapies are used wisely, equitably and in line with each patient’s values and preferences.